U-Blox says it is in talks with suitor Advent over a takeover
"Whether a transaction will materialize is open at this stage," the company said in a statement.
Bloomberg earlier reported on the talks over an acquisition deal that could value U-Blox at more than 1 billion Swiss francs ($1.24 billion).
The shares were up 19% at 1422 GMT at a three-year high, for a total market value of about 1 billion Swiss francs
The Swiss technology group, which went public in 2007, said last week it cut its first-half loss before interest and tax to 7.7 million francs from a loss of 28 million a year earlier.
It cited cost cuts and higher revenues that jumped 32% to 123.4 million francs.
Earlier this year, the company sold a unit making cellular modules for wireless communication to focus on fast-growing navigation and positioning technology used in cars, robots and farm equipment.
Advent did not immediately respond to requests for comment.
($1 = 0.8048 Swiss francs)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
32 minutes ago
- Bloomberg
World Economic Forum Clears Schwab, Names Fink as Co-Chair
By Updated on Save The World Economic Forum has cleared Klaus Schwab of ' material wrongdoing ' after a law firm conducted a review into potential misconduct of the institution's founder. The body also said Blackrock Inc. 's Larry Fink and Roche Holding AG vice chairman Andre Hoffmann will take over the leadership of the WEF board of trustees on an interim basis as co-chairs, according to a statement late Friday. Interim chairman Peter Brabeck-Letmathe is stepping down.
Yahoo
44 minutes ago
- Yahoo
Report – Inter Milan & Roma Were Ready To Agree Deal For France Star Before U-Turn
Inter Milan and Roma reportedly had an agreement for midfielder Manu Kone before a u-turn by the Giallorossi. This according to Italian outlet They report that Roma owners the Friedkins were crucial to the decision to walk away from negotiations to sell the Frenchman. Yesterday, news emerged that Inter Milan are interested in Roma midfielder Manu Kone. The Frenchman has come into the Nerazzurri's sights as a reinforcement in holding midfield. Reports indicate that Inter put a bid of around €45 million on the table. However, Roma have decided to reject that offer from the Nerazzurri. They have, for all intents and purposes, taken Kone off the market this summer. Report – Inter & Roma Had Manu Kone Agreement Before U-Turn MILAN, ITALY – NOVEMBER 17: Manu Kone' of France in action during the UEFA Nations League 2024/25 League A Group A2 match between Italy and France at on November 17, 2024 in Milan, Italy. (Photo by) According to the Gazzetta dello Sport, though, Roma had initially been open to selling Kone. Inter approached the Giallorossi recently. And they received permission to start negotiating with the player. And Kone himself would have been more than willing to make the move. The 24-year-old had an informal agreement with the Nerazzurri already. However, today Roma have made something of an about face as far as Inter's interest in Kone. The Giallorossi board spent the day discussing the possibility of selling the France international internally. On the one hand, a big fee for Kone would have financed some transfer business the other way, including signings of Jadon Sancho and Leon Bailey. The Gazzetta report that even Roma coach Gian Piero Gasperini would have been willing to make the sale. However, the Gazzetta dello Sport report, Roma owner Dan Friedkin pulled the plug. After seeing what the fan reaction was and considering the importance of Kone to the team, he decided that Kone is not for sale this summer.
Yahoo
an hour ago
- Yahoo
Eli Lilly raising GLP-1 prices abroad raises more questions about US pricing: BofA analyst
Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing in peer developed nations. The effort, known as Most Favored Nations pricing, has been a goal of Trump's since his first term. He has doubled down on the efforts this year, giving pharma companies 60 days to implement changes in pricing in what he deems "freeloading" nations. The US drug economy differs from European and other developed nations, which rely on the government to negotiate prices with drugmakers, resulting in lower prices globally. "While we agree that the costs for breakthrough medicines should be more fairly shared across developed countries, we must also address the underlying structural issues in the US that have contributed to high drug prices. The US system is complex and opaque," Lilly said in a statement Thursday. The stock was up 1% in trading Friday. Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America Securities research analyst Tim Anderson questioned who would actually be impacted by the raised prices. "LLY has announced it will raise GLP-1 pricing in the UK by a healthy margin (a doubling of price, but it's unclear to whom this higher price realistically applies). It expects to do something similar in other European countries (but worth appreciating: in most European markets, there aren't price agreements in place between GLP-1 manufacturers and governments, meaning these are out-of-pocket spending markets)," Anderson wrote. Ultimately, whether or not the move results in lower US prices remains a question, though Anderson believes it likely will not. "Does this mean it will actually cut the price on the GLP-1s in the US (and on other medicines)? To us, the answer is quite likely no, or at least, not in a way that creates P&L [profit and loss planning ] risk," he wrote. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
